Shanyun Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shanyun Wu has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Meixing Yu
Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510180, China
2 shared publications - Xinxin Xiong
Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China
2 shared publications - Andy Peng Xiang
Center for Stem Cell Biology and Tissue Engineering, Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-Sen University, Guangzhou 510080, China
1 shared publication Charlotte L Zhang
Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China
1 shared publicationChengbin Guo
Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China
1 shared publication- Daniel Tomas Baptista‐Hon
Faculty of Medicine Macau University of Science and Technology Macau SAR China
1 shared publication
Latest Publications
- Open Access
- 30 July 2021
- Published by Oxford University Press (OUP) in Precision Clinical Medicine
- Vol. 4 (3) , 149-154
The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera
To assess the impact of the key non-synonymous amino acid substitutions in the RBD of the spike protein of SARS-CoV-2 variant B.1.617.1 (dominant variant identified in the current India outbreak) on the infectivity and neutralization activities of the immune sera, L452R and E484Q (L452R-E484Q variant), pseudotyped virus was constructed (with the D614G background). The impact on binding with the neutralizing antibodies was also assessed with an ELISA assay. Pseudotyped virus carrying a L452R-E484Q variant showed a comparable infectivity compared with D614G. However, there was a significant reduction in the neutralization activity of the immune sera from non-human primates vaccinated with a recombinant receptor binding domain (RBD) protein, convalescent patients, and healthy vaccinees vaccinated with an mRNA vaccine. In addition, there was a reduction in binding of L452R-E484Q-D614G protein to the antibodies of the immune sera from vaccinated non-human primates. These results highlight the interplay between infectivity and other biologic factors involved in the natural evolution of SARS-CoV-2. Reduced neutralization activities against the L452R-E484Q variant will have an impact on health authority planning and implications for the vaccination strategy/new vaccine development.
- 30 July 2021
- Published by Oxford University Press (OUP) in Precision Clinical Medicine
- Vol. 4 (3) , 149-154
Open AccessThe SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera
To assess the impact of the key non-synonymous amino acid substitutions in the RBD of the spike protein of SARS-CoV-2 variant B.1.617.1 (dominant variant identified in the current India outbreak) on the infectivity and neutralization activities of the immune sera, L452R and E484Q (L452R-E484Q variant), pseudotyped virus was constructed (with the D614G background). The impact on binding with the neutralizing antibodies was also assessed with an ELISA assay. Pseudotyped virus carrying a L452R-E484Q variant showed a comparable infectivity compared with D614G. However, there was a significant reduction in the neutralization activity of the immune sera from non-human primates vaccinated with a recombinant receptor binding domain (RBD) protein, convalescent patients, and healthy vaccinees vaccinated with an mRNA vaccine. In addition, there was a reduction in binding of L452R-E484Q-D614G protein to the antibodies of the immune sera from vaccinated non-human primates. These results highlight the interplay between infectivity and other biologic factors involved in the natural evolution of SARS-CoV-2. Reduced neutralization activities against the L452R-E484Q variant will have an impact on health authority planning and implications for the vaccination strategy/new vaccine development.
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Identification of Autophagy‐Related Prognostic Signature and Analysis of Immune Cell Infiltration in Low‐Grade Gliomas
Autophagy plays an important role in cancer. Many studies have demonstrated that autophagy‐related genes (ARGs) can act as a prognostic signature for some cancers, but little has been known in low‐grade gliomas (LGG). In our study, we aimed to establish a prognostical model based on ARGs and find prognostic risk‐related key genes in LGG. In the present study, a prognostic signature was constructed based on a total of 8 ARGs (MAPK8IP1, EEF2, GRID2, BIRC5, DLC1, NAMPT, GRID1, and TP73). It was revealed that the higher the risk score, the worse was the prognosis. Time‐dependent ROC analysis showed that the risk score could precisely predict the prognosis of LGG patients. Additionally, four key genes (TGFβ2, SERPING1, SERPINE1, and TIMP1) were identified and found significantly associated with OS of LGG patients. Besides, they were also discovered to be strongly related to six types of immune cells which infiltrated in LGG tumor. Taken together, the present study demonstrated the promising potential of the ARG risk score formula as an independent factor for LGG prediction. It also provided the autophagy‐related signature of prognosis and potential therapeutic targets for the treatment of LGG.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccessIdentification of Autophagy‐Related Prognostic Signature and Analysis of Immune Cell Infiltration in Low‐Grade Gliomas
Autophagy plays an important role in cancer. Many studies have demonstrated that autophagy‐related genes (ARGs) can act as a prognostic signature for some cancers, but little has been known in low‐grade gliomas (LGG). In our study, we aimed to establish a prognostical model based on ARGs and find prognostic risk‐related key genes in LGG. In the present study, a prognostic signature was constructed based on a total of 8 ARGs (MAPK8IP1, EEF2, GRID2, BIRC5, DLC1, NAMPT, GRID1, and TP73). It was revealed that the higher the risk score, the worse was the prognosis. Time‐dependent ROC analysis showed that the risk score could precisely predict the prognosis of LGG patients. Additionally, four key genes (TGFβ2, SERPING1, SERPINE1, and TIMP1) were identified and found significantly associated with OS of LGG patients. Besides, they were also discovered to be strongly related to six types of immune cells which infiltrated in LGG tumor. Taken together, the present study demonstrated the promising potential of the ARG risk score formula as an independent factor for LGG prediction. It also provided the autophagy‐related signature of prognosis and potential therapeutic targets for the treatment of LGG.